WELL Health: Canaccord Increases Price Target To $8.50 Following Bought Deal

This morning Canaccord Genuity raised their 12-month price target on WELL Health Technologies (TSX: WELL) to C$8.50 from C$8.00 and reiterated their Speculative Buy recommendation on the stock following the close of their recent $80 million bought deal.

Doug Taylor, Canaccord’s analyst, now estimates that the company holds roughly $114 million in pro forma cash. Funds from the recent financing are expected to go towards “organic growth initiatives, including its recent apps.health launch, and for additional M&A and strategic investments.”

Taylor says, “Financing strengthens an already sizable war chest for accretive capital allocation.” He adds that the sizeable $114 million in cash WELL has now will go towards M&A or a list of strategic investments, such as the following.

  1. Medical and/or allied health clinics (WELL Health Clinic Network and WELL Allied)
  2. EMR platforms (WELL EMR)
  3. Digital health companies with an emphasis on patient engagement technologies (WELL Digital Health Apps)
  4. Cybersecurity (Cycura)

Although since the Circle Medical deal that was signed at the beginning of September, there has been no new deals, Taylor says, “we understand
the company currently has on the order of 10 signed letters of intent (LOI) in its M&A pipeline, noting that timing and probability of closing from the LOI stage are variable.”

Taylor then touches on their forecast for WELL’s third-quarter results, which will be announced in November. Taylor says that they expect a small growth in Digital Services revenue over the second quarter. This quarter will include early contributions from the Cycura acquisition.

Taylor expects third-quarter revenue to be $11 million and Adjusted EBITDA to be ($0.4) million. His full 2020 year revenue estimate is $44 million with EBITDA of ($0.8) million.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Why the Market May Be Misreading Iran | David Woo

Why US Fertilizer Supply Could Matter a Lot More Now | Pat Varas – Sage Potash

Roscan Gold: Mali Discount Hits Kandiole PEA

Recommended

Antimony Resources Expands New Discovery Following Trenching

Silver47 Kicks Off 7,000-Meter Drill Campaign at Nevada’s Hughes Project

Related News

Lundin Mining: BMO Lowers Targets, Rating Based On Expected Lackluster News Flow

On August 19, BMO Capital Markets lowered their 12-month price target on Lundin Mining Corporation...

Friday, August 20, 2021, 11:21:00 AM

Eldorado Gold: BMO Reiterates $20 Price Target

This week Eldorado Gold (TSX: ELD) provided full year 2022 production and cost guidance as...

Saturday, January 22, 2022, 03:28:00 PM

Peloton Sees Consensus Targets Tumble Amid Recalls

Peloton Interactive (NASDAQ: PTON) investors had a very rough week last week after falling almost...

Tuesday, May 11, 2021, 11:48:00 AM

Sundial Growers: Canaccord Initiates Coverage With US$0.30 Price Target

This morning, Canaccord Genuity initiated coverage on Sundial Growers (NASDAQ: SNDL) with a US$0.30 price...

Monday, November 16, 2020, 12:12:19 PM

PI Financial Discontinues Coverage On Medipharm Labs, Heritage Cannabis

Friday evening following the close of markets, a note was sent out by PI Financials...

Monday, September 28, 2020, 07:42:00 AM